How Do Patient-Derived Xenograft Cancer Therapy Models Work?

Gideon Anderson

There is a lack of randomized data to recommend systemic therapy for many malignancies. Even though gene expression profiling combined with proteomics has improved diagnosis, classification, and prognosis, many tumors remain incurable due to a lack of treatment alternatives. Patient-derived xenograft (PDX) models are being used to generate rare cancers. Unfortunately, the effectiveness of preclinical studies and accurate clinical results seldom coincide. Better preclinical modeling will be required. Traditional research methods, such as randomized control trials, may be used to assess the fast-expanding area of targeted, personalized therapy, which is the future of cancer treatment.

The Xenograft Models

According to biomarkers for predictive and prognostic malignancies, clinical judgment and knowledge are more important than published clinical data in creating personalized cancer treatment. Below is a list of PDX Models for different malignancies.

Mixed Mullerian Cancer

Malignant neoplasms of the uterus with epithelial and mesenchymal components have been discussed for more than 150 years. They provided researchers with a reliable way to evaluate medication efficacy before putting it through clinical trials. Preclinical models, such as mixed Mullerian cancer models, are needed to assess medications that target malignant mixed Mullerian tumor cancer.

Prostate Cancer

Prostate cancer is a complex illness to treat since it has so many symptoms. This makes medication development and scientific research difficult. Preclinical models such as patient-derived xenografts (PDX) must be utilized to evaluate medications primarily used to treat prostate cancer. Unfortunately, producing prostate cancer pdx models is very difficult.

Testicular Cancer

Testicular cancer is one of the most common solid tumors in young men aged 20–40, and its incidence is on the rise worldwide. PDX models are well-known for correctly predicting medication efficacy before being put into clinical trials as the best predictive preclinical model. These models may be used for mechanistic study and pre-clinical testing of novel testicular cancer research and treatment approaches.

Acute Myeloid Leukemia 

Cancer of the myeloid hematopoiesis AML is a kind of cancer that is genetically diverse. Blood cancer patient-derived xenograft (PDX) models are often transitory and non-transferable from one passage to the next. They don’t cause disease or death, and they don’t manifest themselves in any way. Because PDX models for blood cancer are permanent, they may be used to investigate disease recurrence after a treatment challenge and the effectiveness of new medicines in treating drug-resistant cancers.

Brain Cancer 

While patient survival in pediatric oncology has improved dramatically in many areas in recent decades, the prognosis for most children with malignant brain tumors remains grim. Fresh tissue, newly obtained cell suspensions, or short-cropped neurospheres are currently used to make PDXs for juvenile brain tumors in immunosuppressed rats and mice.


Cholangiocarcinoma is a biliary system cancer with a bad prognosis. This fatal disease urgently requires effective, customized therapies. Gallbladder cancer is very uncommon. They are, nevertheless, very aggressive and have a dismal prognosis. Due to their rarity, appropriate treatment studies have been hampered.



As biomarker-driven therapy has become increasingly important in the treatment of cancer patients, new trial designs targeting biomarker-identified patient groups have been developed. In PDX models in tumor tissue, pathohistology, genetic/epigenetic, and therapeutic responses to anti-cancer treatments are reproduced. Individual drug and treatment responses may be predicted using PDX models, allowing for the practice of personalized medicine. They’re also used to figure out a few of the mechanisms contributing to treatment resistance in different tumor kinds. However, tumor cell proliferation and tumor microenvironment heterogeneity remain a possibility. In organoid-derived PDX models, biofluorescence imaging may be utilized to identify micrometastatic lesions.